Zura Bio Limited
NASDAQ:ZURABiotechnology
+$0.07 today
- Market cap
- $92.96M
- Beta
- 0.03
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.67
Volume 3.02M
Average 0.75M
ZURA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Zura Bio LimitedNASDAQ: ZURA
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $5.01M rose 37.4% year over year, ahead of the -37.2% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 94.3% from the prior quarter. Over 3 fiscal years it compounded at +233.0% a year.
Context
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +37.4% holds above the trailing-twelve-month pace of -37.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 12.33M USD
- Year-over-year change
- -26.6%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.33M | -26.6% |
| FY2024 | 2024-12-31 | 16.8M | +74.0% |
| FY2023 | 2023-12-31 | 9.66M | +2790.7% |
| FY2022 | 2022-12-31 | 334K | — |
| FY2021 | 2021-12-31 | 0 | — |
Stock-Based Compensation vs competitors
How ZURA compares with its peers on the latest reported figures
- ZURA's LTM Mar 2026 stock-based compensation of $11.32M is the 4th largest of the 11 companies compared; the peer median is $7.09M.
- Its year-over-year change of -37.2% is the 9th highest of 11, against a peer median of -30.5%.
- Over three fiscal years its annual growth of +233.0% compares with a peer median of -7.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $23.07M | -33.2% | -6.0% | 50.9% | |
| LTM Mar 2026 | $15.77M | -32.9% | -11.7% | 22.8% | |
| LTM Mar 2026 | $11.51M | -28.1% | +4.4% | 5116.0% | |
ZURAZura Bio Limited | LTM Mar 2026 | $11.32M | -37.2% | +233.0% | — |
| LTM Mar 2026 | $8.17M | -33.3% | -9.2% | 59.0% | |
| LTM Mar 2026 | $7.36M | +42.2% | — | 26.1% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $6.82M | +13.6% | +50.8% | — |
| LTM Mar 2026 | $6.04M | -48.6% | -13.0% | — | |
| LTM Mar 2026 | $5.08M | +64.3% | -10.8% | 7.1% | |
| LTM Mar 2026 | $2.64M | +336.0% | +112.4% | — | |
| LTM Mar 2026 | $1.52M | -69.5% | — | — | |
| Peer median (excluding ZURA) | $7.09M | -30.5% | -7.6% | 38.5% | |
Competitors are the stored peer set for ZURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 8.42M | (27.33M) | (60.56M) | (52.4M) | (68.65M) |
| Depreciation & Amortization | 0 | 0 | 0 | 9K | 49K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 334K | 9.66M | 16.8M | 12.33M |
| Change in Working Capital | (235.6K) | 3.54M | 5.12M | 2.31M | (3.63M) |
| Accounts Receivables | 2.87K | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 288.29K | 0 | 4.21M | (2.16M) |
| Other Working Capital | (238.47K) | 3.25M | 5.12M | (1.91M) | (1.47M) |
| Other Non-Cash Items | (9.28M) | 22.26M | 30.74M | 5.21M | (4.91M) |
| Operating Cash Flow | (1.1M) | (1.2M) | (15.05M) | (28.08M) | (64.82M) |
| Capital Expenditures | (4) | (12M) | (8M) | (75K) | (113K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (139.38M) | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | (5M) | 0 |
| Investing Cash Flow | (139.38M) | (12M) | (8M) | (5.08M) | (113K) |
| Debt Repayment | (117.38K) | 7.6M | (10M) | 0 | 0 |
| Common Stock Issued | 140.82M | 0 | 116.41M | 60.76M | 5.2M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 505K | (2.83M) | 14.89M | 49.09M | (7.37M) |
| Financing Cash Flow | 141.21M | 14.77M | 121.29M | 109.84M | (2.16M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 729.22K | 1.57M | 98.24M | 76.69M | (67.09M) |
| Free Cash Flow | (1.1M) | (13.2M) | (23.05M) | (28.15M) | (64.93M) |
Zura Bio Limited
NASDAQ:ZURA
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.